Report cover image

Retinoblastoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Publisher Global Markets Direct
Published Aug 30, 2022
Length 47 Pages
SKU # GMD17396343

Description

Retinoblastoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Retinoblastoma - Drugs In Development, 2022, provides an overview of the Retinoblastoma (Oncology) pipeline landscape.
Retinoblastoma is an eye cancer that begins in the retina. Symptoms include white color in the center circle of the eye (pupil), eye redness, vision problems, a different color in each iris and eye swelling. The predisposing factors include age and heredity. Treatment includes chemotherapy, radiation therapy and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Retinoblastoma - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Retinoblastoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Retinoblastoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Retinoblastoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 9 and 1 respectively.
Retinoblastoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Retinoblastoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Retinoblastoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Retinoblastoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Retinoblastoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Retinoblastoma (Oncology)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Retinoblastoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Retinoblastoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

47 Pages
Introduction
Global Markets Direct Report Coverage
Retinoblastoma – Overview
Retinoblastoma – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Retinoblastoma – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Retinoblastoma – Companies Involved in Therapeutics Development
Aileron Therapeutics Inc
APEIRON Biologics AG
Ascentage Pharma Group International
Canget BioTekpharma LLC
Chengdu Kanghong Pharmaceuticals Group Co Ltd
Cothera Bioscience Pty Ltd
Innovation Pharmaceuticals Inc
Oxular Ltd
PepVax Inc
Seneca Therapeutics Inc
Spectocular LLC
Targeted Therapy Technologies LLC
VCN Biosciences SL
Retinoblastoma – Drug Profiles
APG-115 – Drug Profile
conbercept – Drug Profile
Drug to Inhibit MDM2 for Retinoblastoma – Drug Profile
FL-761 – Drug Profile
FL-7729 – Drug Profile
FL-7N1 – Drug Profile
Kevetrin – Drug Profile
lorukafusp alfa – Drug Profile
OXU-003 SR – Drug Profile
PC-002p – Drug Profile
PVX-301 – Drug Profile
sulanemadlin – Drug Profile
SVV-001 – Drug Profile
topotecan – Drug Profile
VCN-01 – Drug Profile
Retinoblastoma – Dormant Projects
Retinoblastoma – Product Development Milestones
Featured News & Press Releases
Feb 08, 2022: Synthetic Biologics announces VCN Biosciences' VCN-01 receives orphan drug designation for retinoblastoma from the U.S. FDA
Oct 12, 2020: Oxular Receives Rare Paediatric Disease and Orphan-Drug Designations for retinoblastoma treatment
Jan 24, 2019: SJD Barcelona Children’s Hospital is, for the first time in the world, treating a childhood cancer of the retina with the oncolytic virus VCN-01
Feb 29, 2016: VCN Biosciences Provides Update on its lead candidate VCN-01
Dec 01, 2015: Cellceutix Receives Rare Pediatric Disease Designation From FDA for Kevetrin for the Treatment of Retinoblastoma
Nov 23, 2015: Cellceutix Receives FDA Orphan Drug Designation for Kevetrin for the Treatment of Retinoblastoma
Aug 23, 2015: Cellceutix Requesting Meeting With FDA on Kevetrin for Pediatric Retinoblastoma
Mar 08, 2013: Cellceutix Announces Positive Preclinical Trial Data Of Kevetrin In Retinoblastoma
Oct 31, 2012: VCN Biosciences at the 2012 Annual Meeting of the European Society of Cell & Gene Therapy in Versailles
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Table 1: Number of Products under Development for Retinoblastoma, 2022
Table 2: Number of Products under Development by Companies, 2022
Table 3: Products under Development by Companies, 2022
Table 4: Number of Products by Stage and Target, 2022
Table 5: Number of Products by Stage and Mechanism of Action, 2022
Table 6: Number of Products by Stage and Route of Administration, 2022
Table 7: Number of Products by Stage and Molecule Type, 2022
Table 8: Retinoblastoma – Pipeline by Aileron Therapeutics Inc, 2022
Table 9: Retinoblastoma – Pipeline by APEIRON Biologics AG, 2022
Table 10: Retinoblastoma – Pipeline by Ascentage Pharma Group International, 2022
Table 11: Retinoblastoma – Pipeline by Canget BioTekpharma LLC, 2022
Table 12: Retinoblastoma – Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, 2022
Table 13: Retinoblastoma – Pipeline by Cothera Bioscience Pty Ltd, 2022
Table 14: Retinoblastoma – Pipeline by Innovation Pharmaceuticals Inc, 2022
Table 15: Retinoblastoma – Pipeline by Oxular Ltd, 2022
Table 16: Retinoblastoma – Pipeline by PepVax Inc, 2022
Table 17: Retinoblastoma – Pipeline by Seneca Therapeutics Inc, 2022
Table 18: Retinoblastoma – Pipeline by Spectocular LLC, 2022
Table 19: Retinoblastoma – Pipeline by Targeted Therapy Technologies LLC, 2022
Table 20: Retinoblastoma – Pipeline by VCN Biosciences SL, 2022
Table 21: Retinoblastoma – Dormant Projects, 2022
List of Figures
Figure 1: Number of Products under Development for Retinoblastoma, 2022
Figure 2: Number of Products under Development by Companies, 2022
Figure 3: Number of Products by Top 10 Targets, 2022
Figure 4: Number of Products by Stage and Top 10 Targets, 2022
Figure 5: Number of Products by Top 10 Mechanism of Actions, 2022
Figure 6: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Figure 7: Number of Products by Routes of Administration, 2022
Figure 8: Number of Products by Stage and Routes of Administration, 2022
Figure 9: Number of Products by Molecule Types, 2022
Figure 10: Number of Products by Stage and Molecule Types, 2022

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us